Pangaia Partners
Information Technology And Services, 3675 Market St, New Jersey, 19104, United States, 201-500 Employees
Phone Number: +18*********
Who is PANGAIA PARTNERS
StemCells, Inc. is currently engaged in clinical development of its HuCNS-SC® platform technology (purified human neural stem cells) as a potential treatment for both neurological and ret...
Read More
- Headquarters: 3675 Market St, New Jersey, 19104, United States
- Date Founded: 1992
- Employees: 201-500
- Revenue: $25 Million to $50 Million
- Active Tech Stack: See technologies
Industry: Information Technology and Services
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from PANGAIA PARTNERS
Pangaia Partners Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Pangaia Partners
Answer: Pangaia Partners's headquarters are located at 3675 Market St, New Jersey, 19104, United States
Answer: Pangaia Partners's phone number is +18*********
Answer: Pangaia Partners's official website is https://neweratech.com/us
Answer: Pangaia Partners's revenue is $25 Million to $50 Million
Answer: Pangaia Partners's SIC: 2834
Answer: Pangaia Partners has 201-500 employees
Answer: Pangaia Partners is in Information Technology and Services
Answer: Pangaia Partners contact info: Phone number: +18********* Website: https://neweratech.com/us
Answer: StemCells, Inc. is currently engaged in clinical development of its HuCNS-SC® platform technology (purified human neural stem cells) as a potential treatment for both neurological and retinal disorders. Top-line data from the Company's Phase I/II clinical trial in thoracic spinal cord injury (SCI) showed measurable gains involving multiple sensory modalities and segments, including the conversion of two of seven patients enrolled in the study with complete injuries to incomplete injuries, post-transplant. The Company's Pathway™ Study, a Phase II proof-of-concept trial in cervical SCI is actively enrolling at eight sites and interim data from the first cohort of six patients is anticipated to be forthcoming in Q4 2015. StemCells, Inc. has also completed its Phase I/II clinical trial in GA-AMD. Top-line results from this study show a positive safety profile and favorable preliminary efficacy data related to visual acuity and contrast sensitivity. The Company's Radiant™ Study, a Phase II proof-of-concept trial in GA-AMD is now enrolling at the first of approximately twenty U.S. sites expected to participate. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination by MRI.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month